
Opinion|Videos|April 10, 2025
Operationalizing TAR-200 and Other Delivery Systems in Practice
Experts discuss whether novel delivery systems in non–muscle-invasive bladder cancer (NMIBC) could be easily adopted in clinical practice and the challenges they anticipate in operationalizing TAR-200 and other novel delivery systems in urology practices.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Looking forward, do you believe novel delivery systems in NMIBC could be easily adopted in clinical practices?
- What challenges do you anticipate in operationalizing TAR-200 and other novel delivery systems in urology practices?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: AUA 2026 Update on Prostate Cancer Early Detection, With Badrinath R. Konety, MBBS
2
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
3
Daniel George, MD, on the significance of the capivasertib approval for PTEN-deficient prostate cancer
4
Amy E. Krambeck, MD, on choosing between CVAC and FANS for suction-based ureteroscopy
5













